(GS71) GSK - Overview
Stock: Vaccines, Hiv, Oncology, Respiratory, Antibiotics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.22% |
| Yield on Cost 5y | 7.28% |
| Yield CAGR 5y | -5.43% |
| Payout Consistency | 94.7% |
| Payout Ratio | 53.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.0% |
| Relative Tail Risk | -9.21% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 48.07 |
| Character TTM | |
|---|---|
| Beta | -0.087 |
| Beta Downside | 0.088 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.82% |
| CAGR/Max DD | 0.70 |
Description: GS71 GSK January 29, 2026
GSK plc (XETRA:GS71) develops, manufactures, and markets a broad portfolio that spans vaccines, specialty medicines, and general medicines across the UK, the US, and global markets. Its operations are split between Commercial Operations and Total R&D, with specialty medicines targeting oncology, respiratory-immunology, inflammation, and infectious diseases such as HIV, while its vaccine suite covers shingles, RSV, seasonal flu, HPV, and a range of pediatric and adult indications.
In FY 2024 GSK reported €46.5 bn in total revenue, of which €12.3 bn came from vaccines-a 7 % YoY increase driven by strong RSV and shingles sales. R&D expenditure reached €5.6 bn, representing 12 % of revenue, and the company’s pipeline now includes 14 late-stage candidates, notably a Phase III mRNA-based RSV vaccine co-developed with CureVac.
Key macro-drivers for GSK’s sector remain robust demand for immunizations in aging populations (global over-65 cohort expected to grow to 1.5 bn by 2030) and sustained government spending on preventative health, which historically lifts vaccine revenue growth rates to 5-6 % CAGR. Additionally, the broader pharmaceutical industry is seeing accelerated adoption of mRNA platforms, a trend GSK is positioning itself to capture through its CureVac partnership.
For a deeper quantitative assessment, you may find it useful to explore GSK’s valuation metrics and scenario analyses on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 5.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.60 > 1.0 |
| NWC/Revenue: -10.86% < 20% (prev -13.29%; Δ 2.43% < -1%) |
| CFO/TA 0.13 > 3% & CFO 7.79b > Net Income 5.49b |
| Net Debt (12.19b) to EBITDA (12.18b): 1.00 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.03b) vs 12m ago -1.33% < -2% |
| Gross Margin: 72.27% > 18% (prev 0.72%; Δ 7156 % > 0.5%) |
| Asset Turnover: 53.88% > 50% (prev 53.94%; Δ -0.05% > 0%) |
| Interest Coverage Ratio: 13.77 > 6 (EBITDA TTM 12.18b / Interest Expense TTM 657.0m) |
Altman Z'' 1.41
| A: -0.06 (Total Current Assets 17.84b - Total Current Liabilities 21.33b) / Total Assets 61.34b |
| B: 0.16 (Retained Earnings 10.02b / Total Assets 61.34b) |
| C: 0.15 (EBIT TTM 9.05b / Avg Total Assets 59.69b) |
| D: 0.22 (Book Value of Equity 10.02b / Total Liabilities 45.59b) |
| Altman-Z'' Score: 1.41 = BB |
Beneish M -3.01
| DSRI: 1.05 (Receivables 7.94b/7.38b, Revenue 32.17b/31.31b) |
| GMI: 0.99 (GM 72.27% / 71.55%) |
| AQI: 1.02 (AQ_t 0.54 / AQ_t-1 0.53) |
| SGI: 1.03 (Revenue 32.17b / 31.31b) |
| TATA: -0.04 (NI 5.49b - CFO 7.79b) / TA 61.34b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of GS71 shares?
Over the past week, the price has changed by +17.02%, over one month by +15.47%, over three months by +26.04% and over the past year by +47.49%.
Is GS71 a buy, sell or hold?
What are the forecasts/targets for the GS71 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 26 | 2.9% |
GS71 Fundamental Data Overview February 07, 2026
Market Cap GBP = 86.84b (100.41b EUR * 0.8648 EUR.GBP)
P/E Trailing = 15.5404
P/E Forward = 10.7875
P/S = 3.0738
P/B = 5.1198
P/EG = 0.4797
Revenue TTM = 32.17b GBP
EBIT TTM = 9.05b GBP
EBITDA TTM = 12.18b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.18b GBP (from shortLongTermDebt, last fiscal year)
Debt = 15.88b GBP (Calculated: Short Term 2.18b + Long Term 13.70b)
Net Debt = 12.19b GBP (from netDebt column, last fiscal year)
Enterprise Value = 99.42b GBP (86.84b + Debt 15.88b - CCE 3.30b)
Interest Coverage Ratio = 13.77 (Ebit TTM 9.05b / Interest Expense TTM 657.0m)
EV/FCF = 21.17x (Enterprise Value 99.42b / FCF TTM 4.70b)
FCF Yield = 4.72% (FCF TTM 4.70b / Enterprise Value 99.42b)
FCF Margin = 14.60% (FCF TTM 4.70b / Revenue TTM 32.17b)
Net Margin = 17.08% (Net Income TTM 5.49b / Revenue TTM 32.17b)
Gross Margin = 72.27% ((Revenue TTM 32.17b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Gross Margin QoQ = 73.58% (prev 72.89%)
Tobins Q-Ratio = 1.62 (Enterprise Value 99.42b / Total Assets 61.34b)
Interest Expense / Debt = 1.05% (Interest Expense 167.0m / Debt 15.88b)
Taxrate = 12.70% (312.0m / 2.46b)
NOPAT = 7.90b (EBIT 9.05b * (1 - 12.70%))
Current Ratio = 0.84 (Total Current Assets 17.84b / Total Current Liabilities 21.33b)
Debt / Equity = 0.98 (Debt 15.88b / totalStockholderEquity, last quarter 16.15b)
Debt / EBITDA = 1.00 (Net Debt 12.19b / EBITDA 12.18b)
Debt / FCF = 2.60 (Net Debt 12.19b / FCF TTM 4.70b)
Total Stockholder Equity = 14.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.20% (Net Income 5.49b / Total Assets 61.34b)
RoE = 37.40% (Net Income TTM 5.49b / Total Stockholder Equity 14.69b)
RoCE = 31.87% (EBIT 9.05b / Capital Employed (Equity 14.69b + L.T.Debt 13.70b))
RoIC = 42.33% (NOPAT 7.90b / Invested Capital 18.66b)
WACC = 4.88% (E(86.84b)/V(102.72b) * Re(5.60%) + D(15.88b)/V(102.72b) * Rd(1.05%) * (1-Tc(0.13)))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.37%
[DCF Debug] Terminal Value 84.96% ; FCFF base≈4.73b ; Y1≈4.17b ; Y5≈3.42b
Fair Price DCF = 22.77 (EV 103.55b - Net Debt 12.19b = Equity 91.36b / Shares 4.01b; r=5.90% [WACC]; 5y FCF grow -14.71% → 2.90% )
EPS Correlation: -7.24 | EPS CAGR: 29.19% | SUE: 0.04 | # QB: 0
Revenue Correlation: 63.64 | Revenue CAGR: 8.62% | SUE: N/A | # QB: 0